United States
LocationRelationship Network
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
GHISLAINE MAXWELL
|
Legal representative |
32
Very Strong
|
72 | |
|
person
Jeffrey Epstein
|
Legal representative |
13
Very Strong
|
10 | |
|
person
Epstein
|
Legal representative |
13
Very Strong
|
19 | |
|
person
MAXWELL
|
Legal representative |
12
Very Strong
|
9 | |
|
organization
Iran
|
Adversarial |
10
Very Strong
|
7 | |
|
person
Davis
|
Legal representative |
10
Very Strong
|
5 | |
|
person
Bodmer
|
Legal representative |
10
Very Strong
|
5 | |
|
person
Dreier
|
Legal representative |
10
Very Strong
|
4 | |
|
person
English
|
Legal representative |
10
Very Strong
|
4 | |
|
person
Boustani
|
Legal representative |
10
Very Strong
|
5 | |
|
person
Torres
|
Legal representative |
10
Very Strong
|
4 | |
|
location
China
|
Unknown |
10
Very Strong
|
4 | |
|
person
Smith
|
Legal representative |
9
Strong
|
5 | |
|
person
Ms. Maxwell
|
Legal representative |
9
Strong
|
4 | |
|
location
China
|
Geopolitical rivals |
9
Strong
|
2 | |
|
person
Sampson
|
Legal representative |
8
Strong
|
4 | |
|
person
Carrillo-Villa
|
Legal representative |
8
Strong
|
2 | |
|
person
Petrov
|
Legal representative |
8
Strong
|
3 | |
|
person
Dominguez
|
Legal representative |
8
Strong
|
2 | |
|
person
Hung
|
Legal representative |
8
Strong
|
2 | |
|
person
Abdellatif El Mokadem
|
Legal representative |
8
Strong
|
2 | |
|
person
Rowe
|
Legal representative |
8
Strong
|
3 | |
|
person
Alindato-Perez
|
Legal representative |
8
Strong
|
2 | |
|
person
Crowell
|
Legal representative |
8
Strong
|
2 | |
|
person
Deutsch
|
Legal representative |
8
Strong
|
2 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| N/A | N/A | Modification of the Non-Prosecution Agreement | United States | View |
| N/A | N/A | Discussion of the Syrian situation, including the legitimacy of Mr. Assad, international response... | Global political context, U... | View |
| N/A | N/A | Clarification of provisions in paragraph 7 of the Non-Prosecution Agreement regarding the selecti... | N/A | View |
| N/A | N/A | Assignment of Independent Third-Party | N/A | View |
| N/A | N/A | Non-prosecution agreement (NPA) intended for broad, complete resolution of matters, including Eps... | N/A | View |
| N/A | N/A | Non-Prosecution Agreement (NPA) entered into by the United States Attorney's Office, Southern Dis... | Southern District of Florida | View |
| N/A | N/A | Agreement regarding Epstein's charges, sentencing, and victim representation. Includes terms for ... | N/A | View |
| N/A | N/A | War with Iran / U.S.-led attack | Iran | View |
| N/A | N/A | Negotiation and execution of a plea agreement | Eleventh Circuit | View |
| N/A | N/A | Cold War | Global | View |
| N/A | N/A | Non-Prosecution Agreement execution | Unspecified | View |
| N/A | N/A | Epstein agrees to plea deal (NPA) for 18 months imprisonment. | Florida | View |
| N/A | N/A | Potential Iranian nuclear targeting of US logistics hubs. | Middle East / Bahrain | View |
| N/A | N/A | Selection of attorney representative for victims | Unspecified | View |
| N/A | N/A | Public protests and Mubarak's time of need | Cairo, Egypt | View |
| N/A | N/A | Suspension of federal Grand Jury investigation. | N/A | View |
| N/A | N/A | US shipment of battery-operated TV sets to Pacific islands. | Pacific Ocean islands | View |
| N/A | N/A | Hypothetical conflict/coalition warfare between US and Iran | Middle East | View |
| N/A | N/A | Potential U.S. attack on Iran | Iran | View |
| N/A | N/A | Suspension of federal Grand Jury investigation | Federal Court | View |
| N/A | N/A | Proposed peace conference to address the Israeli-Palestinian conflict. | U.S. | View |
| N/A | N/A | Palestinian bid for full U.N. membership. | United Nations | View |
| N/A | N/A | United States' decision to pursue warmer ties with Tehran. | International | View |
| N/A | Legal case | United States v. Rodriguez, Case No. 9:09-mj-08308-LRJ | N/A | View |
| N/A | Non-prosecution agreement | Epstein agreed to a sentence of eighteen months' imprisonment on two charges, and in return, the ... | N/A | View |
HOUSE_OVERSIGHT_024874.jpg
This document is page 58 of a Cowen Collaborative Insights financial report dated February 25, 2019, analyzing the cannabis and CBD industry. It details strategic updates, retail distribution benchmarking (store counts), and revenue figures for companies including TGOD, HEXO, Neptune, Organigram, Charlotte's Web, and Tilray. While the content is strictly financial analysis, the document bears the Bates stamp 'HOUSE_OVERSIGHT_024874', indicating it was part of a document production for a US House Oversight Committee investigation, likely related to broader financial inquiries.
HOUSE_OVERSIGHT_024873.jpg
This document is page 57 of a Cowen Collaborative Insights report dated February 25, 2019, detailing the strategies of major Canadian cannabis companies (Aphria, Aurora, Canopy Growth, Cronos, Emblem, and Emerald Health) regarding the hemp and CBD markets. It aggregates quotes from CEO earnings calls and press releases concerning market expansion into Europe and the US, as well as strategic partnerships. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was likely part of a document production for a congressional investigation.
HOUSE_OVERSIGHT_024867.jpg
A Cowen 'Collaborative Insights' financial report page dated February 25, 2019, analyzing the U.S. market for CBD vapor and e-cigarettes. The document projects significant growth in the sector, forecasting CBD vape revenues to reach $360 million by 2020 and comparing this to JUUL's market share. The page includes three figures (95, 96, 97) illustrating sales forecasts and scenario analysis, and bears a House Oversight Committee Bates stamp.
HOUSE_OVERSIGHT_024865.jpg
This document is page 49 of a financial research report by Cowen Collaborative Insights, dated February 25, 2019. It analyzes the market potential for CBD-infused food and confections in the U.S., projecting sales could surpass $400 million by 2020. The document contains charts and sensitivity analyses regarding market share and revenue growth. It bears the Bates stamp HOUSE_OVERSIGHT_024865, indicating it was part of a document production for the House Oversight Committee, though the specific content is strictly market research unrelated to specific individuals.
HOUSE_OVERSIGHT_024860.jpg
A page from a Cowen financial research report dated February 25, 2019, analyzing the U.S. Beauty industry and specifically projecting growth for CBD beauty products. It includes charts forecasting sales growth through 2020. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional investigation, though the page itself contains no direct references to Jeffrey Epstein or illicit activity.
HOUSE_OVERSIGHT_024855.jpg
This document is page 39 of a Cowen Collaborative Insights market research report dated February 25, 2019. It analyzes the market potential for CBD-infused bottled water in the U.S., utilizing Google Trends and Nielsen sales data to project revenue growth through 2020. The document bears the Bates stamp HOUSE_OVERSIGHT_024855 and is watermarked for Michael Cella at Cowen.
HOUSE_OVERSIGHT_024844.jpg
This document is page 28 of a financial research report produced by Cowen on February 25, 2019, analyzing the Nutraceuticals market. It specifically focuses on U.S. CBD sales projections following the 2018 Farm Bill, estimating $2.4 billion in revenue by 2020. The document bears a House Oversight Committee Bates stamp (HOUSE_OVERSIGHT_024844), suggesting it was part of a subpoena or discovery process involving Cowen.
HOUSE_OVERSIGHT_024840.jpg
This document is page 24 of a Cowen Collaborative Insights research report dated February 25, 2019, analyzing the U.S. CBD market. It presents data suggesting the market size is approaching $2 billion based on consumer surveys and increasing Google search trends for CBD products like gummies, creams, and oils. The document bears a House Oversight Bates stamp (024840), indicating it was part of a document production to Congress, though no direct mention of Jeffrey Epstein appears on this specific page.
HOUSE_OVERSIGHT_024832.jpg
This document is page 16 of a 'Cowen Collaborative Insights' market research report dated February 25, 2019. It analyzes U.S. hemp production, providing a statistical table of planted acres by state for 2017 and 2018, showing a significant increase in total acreage. The text discusses economic challenges for the hemp CBD market, including supply saturation and seed costs. While marked with a 'HOUSE_OVERSIGHT' Bates number, this specific page contains no direct mention of Jeffrey Epstein, his associates, or victims; it appears to be part of a larger financial document production.
HOUSE_OVERSIGHT_024825.jpg
A page from a Cowen and Company financial research report dated February 25, 2019, analyzing the U.S. CBD market. The report projects a $16 billion revenue opportunity by 2025, breaking down the market into sectors such as nutraceuticals ($6.4bn), topicals ($4bn), and beverages ($2.4bn). The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was produced as part of a Congressional investigation, potentially related to financial records, though no specific Epstein connection is visible in the text of this specific page.
HOUSE_OVERSIGHT_024819.jpg
A Cowen equity research report titled 'Cowen's Collective View of CBD - Ahead of the Curve Series,' dated February 25, 2019. The document analyzes the U.S. CBD market, projecting a $16 billion opportunity by 2025, and discusses consumer trends, scientific understanding, and hemp cultivation. The document bears a House Oversight Committee Bates stamp (HOUSE_OVERSIGHT_024819) and a watermark indicating it was intended for Michael Cella at Cowen.
HOUSE_OVERSIGHT_024817.jpg
This document is the cover page of a Cowen Equity Research report titled 'Cowen's Collective View of CBD,' dated February 25, 2019. The report provides market analysis and projections for the CBD industry, predicting $16 billion in sales by 2025, and highlights specific stocks (WEED, TLRY, TPB). While the content is strictly financial research, the document bears the Bates stamp 'HOUSE_OVERSIGHT_024817,' indicating it was collected as part of a House Oversight Committee investigation.
HOUSE_OVERSIGHT_024802.jpg
This document is page 166 of a Cannabis Investment Report produced by Ackrell Capital, LLC in December 2017. It details the legal and financial risks associated with the cannabis industry, specifically focusing on conflicts between federal and state laws regarding taxation, banking access, trademark registration, and bankruptcy protection. The document bears the Bates stamp 'HOUSE_OVERSIGHT_024802,' indicating it was included in a document production to the House Oversight Committee.
HOUSE_OVERSIGHT_024801.jpg
This document is page 165 of a report by Ackrell Capital, LLC, dated 2017, detailing 'Chapter IX: Cannabis Industry Risk Factors.' It outlines the legal and financial risks associated with the cannabis industry in relation to U.S. Federal Law, specifically the Controlled Substances Act (CSA), warning of potential asset seizure, imprisonment, and regulatory hurdles regarding interstate commerce. The document bears a 'HOUSE_OVERSIGHT' bates stamp, indicating it is part of a larger document production to the House Oversight Committee.
HOUSE_OVERSIGHT_024796.jpg
This document is page 160 of a Cannabis Investment Report dated December 2017, authored by Ackrell Capital. It profiles four companies: Strainz, Teewinot Life Sciences, Tikun Olam, and Treez, providing their locations, websites, and brief business descriptions. The document bears the Bates stamp HOUSE_OVERSIGHT_024796, indicating it was part of a document production for a House Oversight Committee investigation.
HOUSE_OVERSIGHT_024787.jpg
This document is page 151 of a report titled 'Top 100 Private Cannabis Companies 2018' produced by Ackrell Capital. It profiles four companies: Humboldt Legends, Incense Specialties, Jetty Extracts, and Kikoko, providing their locations, websites, and brief business descriptions. The document bears a 'HOUSE_OVERSIGHT_024787' stamp, indicating it was part of a document production for a House Oversight Committee investigation.
HOUSE_OVERSIGHT_024768.jpg
This document is page 132 of a December 2017 Cannabis Investment Report by Ackrell Capital, LLC. It provides a detailed comparison of Canadian stock markets (TSX, TSXV, and CSE) regarding their suitability for cannabis-related companies, listing requirements, and market values. The document bears a 'HOUSE_OVERSIGHT_024768' Bates stamp, indicating it was part of a document production to the House Oversight Committee, though no specific individuals (Epstein or otherwise) are named in the text of this specific page.
HOUSE_OVERSIGHT_024763.jpg
This document is page 127 of a report by Ackrell Capital titled 'Capital Markets for Cannabis Companies.' It provides a financial summary of Canadian publicly traded cannabis-related companies as of November 30, 2017, including market value and revenue data for companies on the TSX, TSXV, and CSE. The text also references the positive market impact of Prime Minister Justin Trudeau's legislative announcements and an investment by Constellation Brands into Canopy Growth. The document bears a 'HOUSE_OVERSIGHT' Bates stamp.
HOUSE_OVERSIGHT_024762.jpg
This document is page 126 from a December 2017 Cannabis Investment Report by Ackrell Capital. It features a detailed comparison table of U.S. stock markets (Nasdaq, NYSE, and OTC), analyzing them by tiers, listed companies, market value, and regulatory requirements. The document bears the Bates stamp 'HOUSE_OVERSIGHT_024762', indicating it was obtained during a House Oversight Committee investigation, likely related to financial records involving major banks or investment firms.
HOUSE_OVERSIGHT_024759.jpg
This document is page 123 of a report by Ackrell Capital regarding capital markets for cannabis companies, bearing a House Oversight Bates stamp. It presents statistical data on capital raised by U.S. publicly traded cannabis companies for the twelve months ending September 30, 2017, breaking down amounts by exchange (Nasdaq, NYSE, OTC). While part of a document production likely related to broader financial investigations (possibly involving banks linked to Epstein), this specific page contains no direct references to Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024758.jpg
This document is page 122 of a December 2017 Cannabis Investment Report by Ackrell Capital. It provides a financial summary and stock price performance analysis of U.S. publicly traded cannabis-related companies as of November 2017. The report notes that the election of Donald Trump and the confirmation of Jeff Sessions did not negatively impact the stock performance of these companies. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production to Congress.
HOUSE_OVERSIGHT_024757.jpg
This page from an Ackrell Capital report details capital raised by publicly traded cannabis companies for the year ending September 30, 2017, highlighting that Canadian companies raised significantly more capital than those in the U.S. or Australia. It also provides an overview of the U.S. public capital markets for cannabis, noting that while a few trade on major exchanges like Nasdaq and NYSE, the vast majority are "penny" stocks on the OTC market characterized by high risk and regulatory scrutiny from the SEC and FINRA.
HOUSE_OVERSIGHT_024756.jpg
This document is page 120 of a December 2017 Cannabis Investment Report by Ackrell Capital. It analyzes the stock price performance and capital raising activities of cannabis-related companies in the U.S., Canada, and Australia, noting resilience despite U.S. political changes (Trump/Sessions) and growth driven by Canadian legislation and strategic investments. The document bears a 'HOUSE_OVERSIGHT' stamp, but contains no direct mentions of Jeffrey Epstein or his known associates on this specific page.
HOUSE_OVERSIGHT_024755.jpg
This document is page 119 of a report by Ackrell Capital titled 'Capital Markets for Cannabis Companies.' It analyzes listing requirements for cannabis companies on US, Canadian, and Australian stock exchanges (NYSE, Nasdaq, OTC, TSX, CSE, ASX). It includes a statistical table summarizing market values, enterprise values, and revenue averages for cannabis-related companies as of November 30, 2017. The document bears a House Oversight Committee stamp.
HOUSE_OVERSIGHT_024754.jpg
This document is page 118 of a Cannabis Investment Report authored by Ackrell Capital in December 2017. It analyzes public capital markets, detailing strategic investments by major corporations like Constellation Brands and Scotts Miracle-Gro into the cannabis sector, and discusses market valuations and regulatory landscapes in the US, Canada, and abroad. The document bears a House Oversight stamp (024754), indicating it was likely gathered as evidence in a congressional investigation, though Jeffrey Epstein is not mentioned on this specific page.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity